Catabasis Pharmaceuticals
 | |
| Public | |
| Traded as | NASDAQ: CATB Russell Microcap Index component |
| ISIN | 🆔 |
| Industry | Pharmaceuticals |
| Founded 📆 | 2008 |
| Founder 👔 | |
| Headquarters 🏙️ | Cambridge, Massachusetts |
Area served 🗺️ | |
Key people | Jill C. Milne (CEO)
Joanne M. Donovan (Chief Medical Officer) Andrew Nichols (Chief Scientific Officer), Deirdre A. Cunnane (Chief Legal Officer) |
| Products 📟 | Orally-delivered pharmaceuticals |
| Members | |
Number of employees | 24 (March 2019) |
| 🌐 Website | [Lua error in Module:WikidataIB at line 665: attempt to index field 'wikibase' (a nil value). ] |
| 📇 Address | |
| 📞 telephone | |
Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company.[1] Their lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy.
In Catabasis’s Phase 2 MoveDMD clinical trial and open-label extension, edasalonexent was shown to preserve muscle function as assessed by the North Star Ambulatory Assessment and Timed Function Tests compared with the rate of change during an off-treatment control period. It also showed a significant decrease in CRP, muscle enzymes including CK, and decrease in heart rate to age-normative values.
References[edit]
- ↑ "Our Story - Our Company - Catabasis". www.catabasis.com. Retrieved 2017-02-17.
This article "Catabasis Pharmaceuticals" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Catabasis Pharmaceuticals. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
